Yanan Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yanan Yu has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Huanhuan Xu
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publicationsJing Xiao
School of Public Health, Nantong University, Nantong, China
2 shared publicationsJun Liu
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications- Jun Liu
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications Kai Zhi
China Academy of Chinese Medical Sciences, Beijing, China
2 shared publicationsPengli Su
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 27 July 2026
- Published by Wolters Kluwer Health in Guidelines and Standards of Chinese Medicine
- Vol. 4 (3) , 207-212
Leveraging multibiomarkers for precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome: a real-world observational study protocol
Objective: To assess the diagnostic value of multiple biomarkers, including blood lipid, coagulation, and inflammatory markers, both individually and in combination, for assisting the precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome (CHD-PBSS) in a real-world observational study, thereby providing a scientific basis for future research on the precision diagnosis of CHD-PBSS. Methods: This is a multicenter, real-world observational study designed to recruit 360 patients aged 35 to 70 years with chronic stable CHD from several medical institutions, including Beijing First Hospital of Integrated Chinese and Western Medicine, Yichang Hospital of Traditional Chinese Medicine (TCM), and Huanggang Hospital of TCM. Patients with CHD-PBSS were assigned to the PBSS group ( n = 180), whereas those with CHD but without PBSS (CHD-NPBSS) were assigned to the NPBSS group (n=180). We compared the levels of blood lipid, coagulation, and inflammatory biomarkers between the 2 groups and subsequently evaluated the diagnostic accuracy of these biomarkers, both individually and in combination, for identifying PBSS in patients with CHD. Discussion: The precision diagnosis of PBSS, a critical syndrome in CHD, is crucial for developing effective prevention and management strategies within the framework of TCM. This study aims to identify clinical diagnostic biomarkers of CHD-PBSS through real-world clinical trials, providing a theoretical basis for achieving accurate TCM syndrome diagnosis. However, the observational design has inherent limitations, as it only offers basic demographic information and does not allow for causal inference. In addition, the complexity of TCM syndromes and the subjectivity of clinicians’ judgements may introduce information and selection biases, potentially affecting the accuracy of the results.
- 27 July 2026
- Published by Wolters Kluwer Health in Guidelines and Standards of Chinese Medicine
- Vol. 4 (3) , 207-212
Open AccessLeveraging multibiomarkers for precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome: a real-world observational study protocol
Objective: To assess the diagnostic value of multiple biomarkers, including blood lipid, coagulation, and inflammatory markers, both individually and in combination, for assisting the precision diagnosis of coronary heart disease with phlegm and blood stasis syndrome (CHD-PBSS) in a real-world observational study, thereby providing a scientific basis for future research on the precision diagnosis of CHD-PBSS. Methods: This is a multicenter, real-world observational study designed to recruit 360 patients aged 35 to 70 years with chronic stable CHD from several medical institutions, including Beijing First Hospital of Integrated Chinese and Western Medicine, Yichang Hospital of Traditional Chinese Medicine (TCM), and Huanggang Hospital of TCM. Patients with CHD-PBSS were assigned to the PBSS group ( n = 180), whereas those with CHD but without PBSS (CHD-NPBSS) were assigned to the NPBSS group (n=180). We compared the levels of blood lipid, coagulation, and inflammatory biomarkers between the 2 groups and subsequently evaluated the diagnostic accuracy of these biomarkers, both individually and in combination, for identifying PBSS in patients with CHD. Discussion: The precision diagnosis of PBSS, a critical syndrome in CHD, is crucial for developing effective prevention and management strategies within the framework of TCM. This study aims to identify clinical diagnostic biomarkers of CHD-PBSS through real-world clinical trials, providing a theoretical basis for achieving accurate TCM syndrome diagnosis. However, the observational design has inherent limitations, as it only offers basic demographic information and does not allow for causal inference. In addition, the complexity of TCM syndromes and the subjectivity of clinicians’ judgements may introduce information and selection biases, potentially affecting the accuracy of the results.
- Open Access
- 24 March 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 101
OptiSyn: an interpretable, multi-omics–driven graph convolutional network framework for synergy-oriented drug combination design in disease treatment
Background: Bioinformatics and large-scale computational modelling have emerged as essential research fields in modern biomedical science, enabling drug discovery and therapeutic optimisation. A unique and potent technical framework for the modernisation and mechanistic clarification of traditional Chinese medicine (TCM) formulations is provided by the integration of multidimensional data using systems biology and artificial intelligence (AI) techniques. Methods: Ankylosing spondylitis–associated key hub genes were identified using multi-omics datasets, differential gene expression analysis, weighted gene co-expression network analysis, single-cell transcriptomic analysis, Mendelian randomization, and network module partitioning. In order to predict the optimal drug combinations and synergistic principal-auxiliary therapeutic roles, an interpretable, multi-layer graph convolutional network model was built using network topology features, molecular docking data, empirical clinical medication knowledge, and compound clustering similarity. Results: Eight AS-associated hub genes were found using AS as a representative disease model. A possible TCM formula, ASD-A, comprising Myrrha , Drynariae Rhizoma , Lycii Fructus , Epimedii Folium , Achyranthis Bidentatae Radix , Alpiniae Officinarum Rhizoma , Forsythiae Fructus , Astragali Radix, was prioritised by the proposed model. While ablation studies highlighted the crucial role of multi-source information integration in compound formula screening and the creation of customised intervention methods, model performance evaluation showed strong predictive potential. The identified hub genes were found to be tightly linked to immunological responses and T-cell-mediated immune processes, according to functional enrichment analyses. Experiments conducted both in vivo and in vitro confirmed that ASD-A significantly reduced pro-inflammatory cytokines like IL-6 and TNF-α ( P < 0.05), modulated the proportions of CD80 and CD86 cell subsets, and regulated the expression of important genes like KRAS, SMAD2, and MAPK14 ( P < 0.05). Furthermore, in activated Jurkat cells, ASD-A significantly decreased IL17 fluorescence while increasing Foxp3 fluorescence ( P < 0.05), indicating a rebalancing of the IL17/Foxp3 axis. The roles of major and auxiliary components in controlling hub gene activity were further clarified by formula decomposition analysis of ASD-A. Conclusion: The suggested AI-driven formula design approach provides new insights into combinatorial therapy approaches for AS while also conforming to the TCM theory of Jun-Chen-Zuo-Shi principle. The significant potential of combining contemporary bioinformatics and AI techniques with traditional medicine is demonstrated by this study, which could facilitate efficient and mechanistically informed disease therapy.
- 24 March 2026
- Published by Springer Nature in Chinese Medicine
- Vol. 21 (1) , 101
Open AccessOptiSyn: an interpretable, multi-omics–driven graph convolutional network framework for synergy-oriented drug combination design in disease treatment
Background: Bioinformatics and large-scale computational modelling have emerged as essential research fields in modern biomedical science, enabling drug discovery and therapeutic optimisation. A unique and potent technical framework for the modernisation and mechanistic clarification of traditional Chinese medicine (TCM) formulations is provided by the integration of multidimensional data using systems biology and artificial intelligence (AI) techniques. Methods: Ankylosing spondylitis–associated key hub genes were identified using multi-omics datasets, differential gene expression analysis, weighted gene co-expression network analysis, single-cell transcriptomic analysis, Mendelian randomization, and network module partitioning. In order to predict the optimal drug combinations and synergistic principal-auxiliary therapeutic roles, an interpretable, multi-layer graph convolutional network model was built using network topology features, molecular docking data, empirical clinical medication knowledge, and compound clustering similarity. Results: Eight AS-associated hub genes were found using AS as a representative disease model. A possible TCM formula, ASD-A, comprising Myrrha , Drynariae Rhizoma , Lycii Fructus , Epimedii Folium , Achyranthis Bidentatae Radix , Alpiniae Officinarum Rhizoma , Forsythiae Fructus , Astragali Radix, was prioritised by the proposed model. While ablation studies highlighted the crucial role of multi-source information integration in compound formula screening and the creation of customised intervention methods, model performance evaluation showed strong predictive potential. The identified hub genes were found to be tightly linked to immunological responses and T-cell-mediated immune processes, according to functional enrichment analyses. Experiments conducted both in vivo and in vitro confirmed that ASD-A significantly reduced pro-inflammatory cytokines like IL-6 and TNF-α ( P < 0.05), modulated the proportions of CD80 and CD86 cell subsets, and regulated the expression of important genes like KRAS, SMAD2, and MAPK14 ( P < 0.05). Furthermore, in activated Jurkat cells, ASD-A significantly decreased IL17 fluorescence while increasing Foxp3 fluorescence ( P < 0.05), indicating a rebalancing of the IL17/Foxp3 axis. The roles of major and auxiliary components in controlling hub gene activity were further clarified by formula decomposition analysis of ASD-A. Conclusion: The suggested AI-driven formula design approach provides new insights into combinatorial therapy approaches for AS while also conforming to the TCM theory of Jun-Chen-Zuo-Shi principle. The significant potential of combining contemporary bioinformatics and AI techniques with traditional medicine is demonstrated by this study, which could facilitate efficient and mechanistically informed disease therapy.
- 1 February 2025
- Vol. 45 (1) , 152-159
Effect of add-on therapy with Traditional Chinese Medicine on the survival of patients with anemic lower-risk myelodysplastic syndromes in the real-world setting: a retrospective study.
To illustrate the effect of add-on therapy of Traditional Chinese Medicine (TCM) on the long-term survival of anemic lower-risk myelodysplastic syndromes (LR-MDS) patients. In this study, we conducted a retrospective analysis of the data of patients with LR-MDS who were identified from Shuguang Hospital between January 2006 and June 2020. The Kaplan-Meier method was used to calculate overall survival (OS), while the Cox model was employed to analyze prognostic factors of long-term survival. A total of 162 patients who met the inclusion criteria were divided into two groups: the TCM group (n = 78) or the non-TCM group (n = 84). There were no significant differences in baseline characteristics. The cumulative survival rate of the TCM group was significantly higher than that of the non-TCM group [log-rank P = 0.029, hazard ratio (HR) = 0.484, 95% confidence interval (CI) (0.249, 0.942), P < 0.05]. Patients with longer TCM treatment appeared to have better OS (≥ 12 months vs < 12 months); [HR, 0.166 95% CI (0.055, 0.508), P < 0.001)]. According to the Cox model analysis, the combination of TCM and conventional Western Medicine may be a protective factor affecting the long-term survival of LR-MDS patients [HR = 0.509, 95% CI, (0.261, 0.993), P = 0.048]. The hematologic improvement erythroid response (HI-E) rate of the TCM group was significantly higher than that of the non-TCM group (69.23% vs 52.38%; P = 0.028). However, the duration of HI-E and cases of disease progression after HI-E did not significantly differ from the non-TCM group (P > 0.05). The integration of TCM and Western Medicine has the potential to extend the OS of LR-MDS patients when compared to the use of Western Medicine alone.
- 1 February 2025
- Vol. 45 (1) , 152-159
Effect of add-on therapy with Traditional Chinese Medicine on the survival of patients with anemic lower-risk myelodysplastic syndromes in the real-world setting: a retrospective study.
To illustrate the effect of add-on therapy of Traditional Chinese Medicine (TCM) on the long-term survival of anemic lower-risk myelodysplastic syndromes (LR-MDS) patients. In this study, we conducted a retrospective analysis of the data of patients with LR-MDS who were identified from Shuguang Hospital between January 2006 and June 2020. The Kaplan-Meier method was used to calculate overall survival (OS), while the Cox model was employed to analyze prognostic factors of long-term survival. A total of 162 patients who met the inclusion criteria were divided into two groups: the TCM group (n = 78) or the non-TCM group (n = 84). There were no significant differences in baseline characteristics. The cumulative survival rate of the TCM group was significantly higher than that of the non-TCM group [log-rank P = 0.029, hazard ratio (HR) = 0.484, 95% confidence interval (CI) (0.249, 0.942), P < 0.05]. Patients with longer TCM treatment appeared to have better OS (≥ 12 months vs < 12 months); [HR, 0.166 95% CI (0.055, 0.508), P < 0.001)]. According to the Cox model analysis, the combination of TCM and conventional Western Medicine may be a protective factor affecting the long-term survival of LR-MDS patients [HR = 0.509, 95% CI, (0.261, 0.993), P = 0.048]. The hematologic improvement erythroid response (HI-E) rate of the TCM group was significantly higher than that of the non-TCM group (69.23% vs 52.38%; P = 0.028). However, the duration of HI-E and cases of disease progression after HI-E did not significantly differ from the non-TCM group (P > 0.05). The integration of TCM and Western Medicine has the potential to extend the OS of LR-MDS patients when compared to the use of Western Medicine alone.
- Open Access
- 18 November 2024
- Published by Wolters Kluwer Health in Science of Traditional Chinese Medicine
- Vol. 2 (4) , 284-290
Economic evaluation of Danhong injection for the treatment of chronic stable angina in China: A cost-effectiveness analysis
Objective: Danhong injection (DHI) is commonly used in China to treat chronic stable angina (CSA), demonstrating significant clinical efficacy and safety. The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment (ST) compared with ST alone in patients with CSA. Methods: A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI + ST for CSA. Health outcomes were measured as quality-adjusted life years (QALYs), and societal perspective costs were collected in China. Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed to test the robustness of results to parameter uncertainty. Results: Analysis demonstrated DHI + ST provided 0.8190 QALYs at an average cost of $3644.24, while ST yielded 0.7884 QALYs costing $2739.54 over 1 year. The incremental analysis indicated DHI + ST dominance, with an ICER of $29,588.91 per QALY gained compared with ST. One-way sensitivity analysis confirmed the robustness of base case findings, and probabilistic sensitivity analysis suggested a 61.66% probability of DHI + ST being cost-effective over ST at a $37,663.26 per QALY threshold. Conclusion: From a societal perspective in China, DHI + ST appears cost-effective for the treatment of CSA compared with ST alone. These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.
- 18 November 2024
- Published by Wolters Kluwer Health in Science of Traditional Chinese Medicine
- Vol. 2 (4) , 284-290
Open AccessEconomic evaluation of Danhong injection for the treatment of chronic stable angina in China: A cost-effectiveness analysis
Objective: Danhong injection (DHI) is commonly used in China to treat chronic stable angina (CSA), demonstrating significant clinical efficacy and safety. The present study aimed to estimate the cost-effectiveness of DHI combined with standard treatment (ST) compared with ST alone in patients with CSA. Methods: A Markov model with a 3-month cycle and a 1-year time horizon was used to assess the cost-effectiveness of DHI + ST for CSA. Health outcomes were measured as quality-adjusted life years (QALYs), and societal perspective costs were collected in China. Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed to test the robustness of results to parameter uncertainty. Results: Analysis demonstrated DHI + ST provided 0.8190 QALYs at an average cost of $3644.24, while ST yielded 0.7884 QALYs costing $2739.54 over 1 year. The incremental analysis indicated DHI + ST dominance, with an ICER of $29,588.91 per QALY gained compared with ST. One-way sensitivity analysis confirmed the robustness of base case findings, and probabilistic sensitivity analysis suggested a 61.66% probability of DHI + ST being cost-effective over ST at a $37,663.26 per QALY threshold. Conclusion: From a societal perspective in China, DHI + ST appears cost-effective for the treatment of CSA compared with ST alone. These findings support recommending DHI as a clinically valuable and cost-effective option in CSA treatment guidelines.
- Open Access
- 18 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (9) , 1230
Syn-COM: A Multi-Level Predictive Synergy Framework for Innovative Drug Combinations
Drug prediction and treatment using bioinformatics and large-scale modeling have emerged as pivotal research areas. This study proposes a novel multi-level collaboration framework named Syn-COM for feature extraction and data integration of diseases and drugs. The framework aims to explore optimal drug combinations and interactions by integrating molecular virtuality, similarity clustering, overlap area, and network distance. It uniquely combines the characteristics of Chinese herbal medicine with clinical experience and innovatively assesses drug interaction and correlation through a synergy matrix. Gouty arthritis (GA) was used as a case study to validate the framework’s reliability, leading to the identification of an effective drug combination for GA treatment, comprising Tamaricis Cacumen (Si = 0.73), Cuscutae Semen (Si = 0.68), Artemisiae Annuae Herba (Si = 0.62), Schizonepetae Herba (Si = 0.73), Gleditsiae Spina (Si = 0.89), Prunellae Spica (Si = 0.75), and Achyranthis Bidentatae Radix (Si = 0.62). The efficacy of the identified drug combination was confirmed through animal experiments and traditional Chinese medicine (TCM) component analysis. Results demonstrated significant reductions in the blood inflammatory factors IL1A, IL6, and uric acid, as well as downregulation of TGFB1, PTGS2, and MMP3 expression (p < 0.05), along with improvements in ankle joint swelling in GA mice. This drug combination notably enhances therapeutic outcomes in GA by targeting key genes, underscoring the potential of integrating traditional medicine with modern bioinformatics for effective disease treatment.
- 18 September 2024
- Published by MDPI AG in Pharmaceuticals
- Vol. 17 (9) , 1230
Open AccessSyn-COM: A Multi-Level Predictive Synergy Framework for Innovative Drug Combinations
Drug prediction and treatment using bioinformatics and large-scale modeling have emerged as pivotal research areas. This study proposes a novel multi-level collaboration framework named Syn-COM for feature extraction and data integration of diseases and drugs. The framework aims to explore optimal drug combinations and interactions by integrating molecular virtuality, similarity clustering, overlap area, and network distance. It uniquely combines the characteristics of Chinese herbal medicine with clinical experience and innovatively assesses drug interaction and correlation through a synergy matrix. Gouty arthritis (GA) was used as a case study to validate the framework’s reliability, leading to the identification of an effective drug combination for GA treatment, comprising Tamaricis Cacumen (Si = 0.73), Cuscutae Semen (Si = 0.68), Artemisiae Annuae Herba (Si = 0.62), Schizonepetae Herba (Si = 0.73), Gleditsiae Spina (Si = 0.89), Prunellae Spica (Si = 0.75), and Achyranthis Bidentatae Radix (Si = 0.62). The efficacy of the identified drug combination was confirmed through animal experiments and traditional Chinese medicine (TCM) component analysis. Results demonstrated significant reductions in the blood inflammatory factors IL1A, IL6, and uric acid, as well as downregulation of TGFB1, PTGS2, and MMP3 expression (p < 0.05), along with improvements in ankle joint swelling in GA mice. This drug combination notably enhances therapeutic outcomes in GA by targeting key genes, underscoring the potential of integrating traditional medicine with modern bioinformatics for effective disease treatment.
- Open Access
- 24 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1245825
The application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review
Objectives: Multi-Criteria Decision Analysis (MCDA) has gained increasing attention in supporting drug risk-benefit assessment, pricing and reimbursement, as well as optimization of clinical interventions. The objective of this study was to systematically collect and categorize evaluation criteria and techniques of weighting and scoring of MCDA for drug value assessment.Methods: A systematic review of the literature was conducted across seven databases to identify articles utilizing the MCDA frameworks for the evaluation of drug value. Evaluation criteria mentioned in the included studies were extracted and assigned to 5 dimensions including clinical, economic, innovative, societal and humanistic value. A descriptive statistical analysis was performed on the identified drug value evaluation criteria, as well as the weighting and scoring techniques employed. The more a criterion or technique were mentioned in articles, the more important we consider it.Results: Out of the 82 articles included, 111 unique criteria were identified to evaluate the value of drug. Among the 56 unique criteria (448 times) used to measure clinical value, the most frequently mentioned were “comparative safety/tolerability” (58 times), “comparative effectiveness/efficacy” (56 times), “comparative patient-perceived health/patient reported outcomes” (37 times), “disease severity” (34 times), and “unmet needs” (25 times). Regarding economic value measurement, out of the 20 unique criteria (124 times), the most frequently utilized criteria were “cost of intervention” (17 times), “comparative other medical costs” (16 times), and “comparative non-medical costs” (18 times). Out of the 10 criteria (18 times) for assessing innovative value, “a novel pharmacological mechanism” was the most frequently mentioned criterion (5 times). Among the 22 criteria (73 times) used to measure societal value, “system capacity and appropriate use of intervention” was the most frequently cited criterion (14 times). Out of the 3 criteria (15 times) utilized to measure humanistic value, “political/historical/cultural context” was the most frequently mentioned criterion (9 times). Furthermore, 11 scoring and 11 weighting techniques were found from various MCDA frameworks. “Swing weighting” and “a direct rating scale” were the most frequently used techniques in included articles.Conclusion: This study comprehensively presented the current evaluation dimensions, criteria, and techniques for scoring and weighting in drug-oriented MCDA articles. By highlighting the frequently cited evaluation criteria and techniques for scoring and weighting, this analysis will provide a foundation to reasonably select appropriate evaluation criteria and technique in constructing the MCDA framework that aligns with research objectives.
- 24 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1245825
Open AccessThe application of multi-criteria decision analysis in evaluating the value of drug-oriented intervention: a literature review
Objectives: Multi-Criteria Decision Analysis (MCDA) has gained increasing attention in supporting drug risk-benefit assessment, pricing and reimbursement, as well as optimization of clinical interventions. The objective of this study was to systematically collect and categorize evaluation criteria and techniques of weighting and scoring of MCDA for drug value assessment.Methods: A systematic review of the literature was conducted across seven databases to identify articles utilizing the MCDA frameworks for the evaluation of drug value. Evaluation criteria mentioned in the included studies were extracted and assigned to 5 dimensions including clinical, economic, innovative, societal and humanistic value. A descriptive statistical analysis was performed on the identified drug value evaluation criteria, as well as the weighting and scoring techniques employed. The more a criterion or technique were mentioned in articles, the more important we consider it.Results: Out of the 82 articles included, 111 unique criteria were identified to evaluate the value of drug. Among the 56 unique criteria (448 times) used to measure clinical value, the most frequently mentioned were “comparative safety/tolerability” (58 times), “comparative effectiveness/efficacy” (56 times), “comparative patient-perceived health/patient reported outcomes” (37 times), “disease severity” (34 times), and “unmet needs” (25 times). Regarding economic value measurement, out of the 20 unique criteria (124 times), the most frequently utilized criteria were “cost of intervention” (17 times), “comparative other medical costs” (16 times), and “comparative non-medical costs” (18 times). Out of the 10 criteria (18 times) for assessing innovative value, “a novel pharmacological mechanism” was the most frequently mentioned criterion (5 times). Among the 22 criteria (73 times) used to measure societal value, “system capacity and appropriate use of intervention” was the most frequently cited criterion (14 times). Out of the 3 criteria (15 times) utilized to measure humanistic value, “political/historical/cultural context” was the most frequently mentioned criterion (9 times). Furthermore, 11 scoring and 11 weighting techniques were found from various MCDA frameworks. “Swing weighting” and “a direct rating scale” were the most frequently used techniques in included articles.Conclusion: This study comprehensively presented the current evaluation dimensions, criteria, and techniques for scoring and weighting in drug-oriented MCDA articles. By highlighting the frequently cited evaluation criteria and techniques for scoring and weighting, this analysis will provide a foundation to reasonably select appropriate evaluation criteria and technique in constructing the MCDA framework that aligns with research objectives.